The expression of ALK in ALCL correlates with a favorable prognosis compared with other histological subtypes of PTCL, therefore, autoHCT may be considered in high-risk IPI patients or in second-line therapy. The gene discussed is ALK; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.